Elizabeth Webber

Ms. Elizabeth Webber


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Genetics in Medicine
Verified
Journal Article
Open access
JHJessica Ezzell Hunter
Jessica Ezzell Hunter
SIStephanie A Irving
Stephanie A Irving
LBLeslie G Biesecker
Leslie G Biesecker
Adam H BuchananAdam H Buchanan
Adam H Buchanan
BJBrian Jensen
Brian Jensen
KGKatrina A B Goddard
Katrina A B Goddard
Genome and exome sequencing can identify variants unrelated to the primary goal of sequencing. Detecting pathogenic variants associated with an increased risk of a medical disorder enables clinical interventions to improve future health outcomes in patients and their at-risk relatives. The Clinical Genome Resource, or ClinGen, aims to assess clinical actionability of genes and associated disorders as part of a larger effort to build a central resource of information regarding the clinical relevance of genomic variation for use in precision medicine and research. We developed a practical, standardized protocol to identify available evidence and generate qualitative summary reports of actionability for disorders and associated genes. We applied a semiquantitative metric to score actionability. We generated summary reports and actionability scores for the 56 genes and associated disorders recommended by the American College of Medical Genetics and Genomics for return as secondary findings from clinical genome-scale sequencing. We also describe the challenges that arose during the development of the protocol that highlight important issues in characterizing actionability across a range of disorders. The ClinGen framework for actionability assessment will assist research and clinical communities in making clear, efficient, and consistent determinations of actionability based on transparent criteria to guide analysis and reporting of findings from clinical genome-scale sequencing.Genet Med 18 12, 1258-1268.

21 March 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
EWElizabeth Webber
Elizabeth Webber
TKTia L Kauffman
Tia L Kauffman
EOElizabeth O’cOnnor
Elizabeth O’cOnnor
KGKatrina AB Goddard
Katrina AB Goddard
We systematically reviewed the evidence for the interaction of microsatellite instability status (MSI) and treatment with 5FU in colorectal cancer to determine how well MSI status predicts health outcomes in patients undergoing 5FU-based chemotherapy. We conducted a search of four electronic databases through June 2013. We considered studies that included both colorectal cancer patients treated with 5FU-based chemotherapy and untreated patients with survival outcomes presented by MSI status. We identified 16 studies for qualitative analysis (9,212 patients) with 14 studies eligible for meta-analysis. The microsatellite stable (MSS) group showed an effect of 5FU treatment on disease-free survival (HR of 0.62 [95% CI: 0.54, 0.71]) and overall survival (HR of 0.65 [95% CI: 0.54, 0.79]), indicating that MSS patients who received 5FU treatment had longer survival than MSS patients who were untreated. The effect of 5FU treatment was not statistically significant for microsatellite high (MSI-H) patients for disease-free survival (HR of 0.84 [95% CI: 0.53, 1.32]) or overall survival (HR 0.66 [95% CI: 0.43, 1.03]). However, the summarized point estimates of the effects of 5FU treatment for the MSS and MSI-H groups were not different at a statistically significant level. Our analyses indicate that treatment with 5FU-based chemotherapy improves disease-free and overall survival in CRC patients, but that there is no difference in the effect of treatment based on MSI status. Therefore, the use of MSI status to guide treatment decisions about the use of 5FU treatment for CRC has no significant benefits for patients.

14 October 2019 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
SNSteffie K Naber
Steffie K Naber
SKSuman Kundu
Suman Kundu
KKKaren M Kuntz
Karen M Kuntz
WDWilliam David Dotson
William David Dotson
MWMarc Williams
Marc Williams
IVIris Lansdorp Vogelaar
Iris Lansdorp Vogelaar
Background: Although uniform colonoscopy screening reduces colorectal cancer (CRC) mortality, risk-based screening may be more efficient. We investigated whether CRC screening based on polygenic risk is a cost-effective alternative to current uniform screening, and if not, under what conditions it would be.Methods: The MISCAN-Colon model was used to simulate a hypothetical cohort of US 40-year-olds. Uniform screening was modeled as colonoscopy screening at ages 50, 60, and 70 years. For risk-stratified screening, individuals underwent polygenic testing with current and potential future discriminatory performance (area under the receiver-operating curve [AUC] of 0.60 and 0.65–0.80, respectively). Polygenic testing results were used to create risk groups, for which colonoscopy screening was optimized by varying the start age (40–60 years), end age (70–85 years), and interval (1–20 years).Results: With current discriminatory performance, optimal screening ranged from once-only colonoscopy at age 60 years for the lowest-risk group to six colonoscopies at ages 40–80 years for the highest-risk group. While maintaining the same health benefits, risk-stratified screening increased costs by $59 per person. Risk-stratified screening could become cost-effective if the AUC value would increase beyond 0.65, the price per polygenic test would drop to less than $141, or risk-stratified screening would lead to a 5% increase in screening participation.Conclusions: Currently, CRC screening based on polygenic risk is unlikely to be cost-effective compared with uniform screening. This is expected to change with a greater than 0.05 increase in AUC value, a greater than 30% reduction in polygenic testing costs, or a greater than 5% increase in adherence with screening.

11 October 2018 in Human Mutation
Verified
Journal Article
Closed access
PDF file
EWElizabeth Webber
Elizabeth Webber
JHJessica Ezzell Hunter
Jessica Ezzell Hunter
LBLeslie G. Biesecker
Leslie G. Biesecker
ABAdam H. Buchanan
Adam H. Buchanan
ECElizabeth V. Clarke
Elizabeth V. Clarke
ORon behalf of the ClinGen Resource
on behalf of the ClinGen Resource

1 January 2018 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
SNSteffie K. Naber
Steffie K. Naber
KKKaren M. Kuntz
Karen M. Kuntz
NHNora B. Henrikson
Nora B. Henrikson
MWMarc Williams
Marc Williams
NCNed Calonge
Ned Calonge
ILIris Lansdorp-Vogelaar
Iris Lansdorp-Vogelaar

1 September 2018
Verified
Closed access
ELErin L. Leblanc
Erin L. Leblanc
CPCarrie D. Patnode
Carrie D. Patnode
EWElizabeth Webber
Elizabeth Webber
NRNadia Redmond
Nadia Redmond
MRMegan Rushkin
Megan Rushkin
EOElizabeth A. O’Connor
Elizabeth A. O’Connor